Bloomfield, Gerald S.
Hill, C. Larry
Chiswell, Karen
Cooper, Linda
Gray, Shamea
Longenecker, Chris T.
Louzao, Darcy
Marsolo, Keith
Meissner, Eric G.
Morse, Caryn G.
Muiruri, Charles
Thomas, Kevin L.
Velazquez, Eric J.
Vicini, Joseph
Pettit, April C.
Sanders, Gretchen
Okeke, Nwora Lance
Funding for this research was provided by:
National Institute on Minority Health and Health Disparities (R01MD013493)
National Institutes of Health (K23HL137611, R01MH113438, P30AI110527)
National Institute of General Medical Sciences (P20GM130457)
Article History
Received: 1 February 2023
Revised: 27 April 2023
Accepted: 30 April 2023
First Online: 9 May 2023
Declarations
:
: Dr. Lance Okeke reports consulting fees from Gilead Sciences. Dr. Keith Marsolo reports grants and contracts to his institution from Novartis, Amgen, Seqirus, Genentech, BMS, and Boehringer Ingelheim. Dr. Eric G. Meissner serves on an expert panel for Viiv Healthcare. The other authors report no conflicts of interest relevant to this article.
: The Duke University Health System Institutional Review Board (IRB) served as the single IRB of record (Pro00101663, Pro00101104) with approval of a waiver of informed consent. Using a SMART IRB agreement, all sites relied on Duke for IRB review and approval. All procedures followed were in accordance with the ethical standards of the Declaration of Helsinki of the World Medical Association.
: The Duke University Health System IRB approved a waiver of informed consent.
: Not applicable.